Guardant Health (NASDAQ: GH) reported Q3 EPS of ($0.45), $0.29 better than the analyst estimate of ($0.74). Revenue for the quarter came in at $191.5 million versus the consensus estimate of $170.49 million.

GUIDANCE:

Guardant Health sees FY2024 revenue of $720-725 million, versus the consensus of $695.5 million.

For earnings history and earnings-related data on Guardant Health (GH) click here.